Nuvation Bio Inc
NYSE:NUVB

Watchlist Manager
Nuvation Bio Inc Logo
Nuvation Bio Inc
NYSE:NUVB
Watchlist
Price: 5.215 USD -2.34% Market Closed
Market Cap: $1.8B

Operating Margin

-871%
Current
Improving
by 3 195.4%
vs 3-y average of -4 066.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-871%
=
Operating Income
$-233m
/
Revenue
$26.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-871%
=
Operating Income
$-233m
/
Revenue
$26.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Nuvation Bio Inc
NYSE:NUVB
1.8B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 14 112 companies
7th percentile
-871%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Nuvation Bio Inc
Glance View

Market Cap
1.8B USD
Industry
Pharmaceuticals

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 64 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The firm is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. The company is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.

NUVB Intrinsic Value
2.64 USD
Overvaluation 49%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-871%
=
Operating Income
$-233m
/
Revenue
$26.7m
What is Nuvation Bio Inc's current Operating Margin?

The current Operating Margin for Nuvation Bio Inc is -871%, which is above its 3-year median of -4 066.4%.

How has Operating Margin changed over time?

Over the last 1 years, Nuvation Bio Inc’s Operating Margin has increased from -7 852.6% to -871%. During this period, it reached a low of -7 852.6% on Jun 30, 2024 and a high of -871% on Oct 30, 2025.

Back to Top